Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms.

Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, Zermani R.

Tunis Med. 2013 Mar;91(3):209-15.

2.

Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas.

Gao B, Meng F, Bian W, Chen J, Zhao H, Ma G, Shi B, Zhang J, Liu Y, Xu Z.

Urology. 2006 Aug;68(2):282-6.

PMID:
16904437
3.

Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.

Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14.

PMID:
18549892
5.

Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.

Białas M, Okoń K, Dyduch G, Ciesielska-Milian K, Buziak M, Hubalewska-Dydejczyk A, Sobrinho-Simoes M.

Pol J Pathol. 2013 Jun;64(2):129-35.

6.

Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T.

Dong Y, Liu Q.

J Comput Assist Tomogr. 2012 Jul-Aug;36(4):361-6. doi: 10.1097/RCT.0b013e31825975f8.

PMID:
22805661
7.

Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?

Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U.

World J Surg. 2010 Dec;34(12):3022-8. doi: 10.1007/s00268-010-0744-5.

PMID:
20703467
8.

KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.

Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Bäckdahl M.

Mod Pathol. 2003 Mar;16(3):246-55.

9.

[Pheochromocytoma--pathohistologic and immunohistochemical aspects].

Tatić S, Havelka M, Paunović I, Bozić V, Diklic A, Brasanac D, Janković R, Jancić-Zguricas M.

Srp Arh Celok Lek. 2002 Jul;130 Suppl 2:7-13. Serbian.

PMID:
12584991
10.

Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score.

Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F, Nosé V.

Am J Surg Pathol. 2009 Apr;33(4):599-608. doi: 10.1097/PAS.0b013e318190d12e.

PMID:
19145205
11.

Morphometric analysis of benign and malignant adrenal pheochromocytomas.

Hoffman K, Gil J, Barba J, Liu Z, Pertsemlidis D, Kaneko M, Unger P.

Arch Pathol Lab Med. 1993 Mar;117(3):244-7.

PMID:
8442669
12.

A logistic regression model for predicting malignant pheochromocytomas.

Gao B, Sun Y, Liu Z, Meng F, Shi B, Liu Y, Xu Z.

J Cancer Res Clin Oncol. 2008 Jun;134(6):631-4. Epub 2007 Nov 13.

PMID:
17999082
13.

Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.

Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, Kebebew E.

Ann Surg. 2009 Dec;250(6):983-90. doi: 10.1097/SLA.0b013e3181b248bb.

PMID:
19661783
14.

Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.

Guillemot J, Thouënnon E, Guérin M, Vallet-Erdtmann V, Ravni A, Montéro-Hadjadje M, Lefebvre H, Klein M, Muresan M, Seidah NG, Anouar Y, Yon L.

J Mol Endocrinol. 2012 Feb 6;48(2):115-27. doi: 10.1530/JME-11-0077. Print 2012 Apr.

PMID:
22217803
15.

[Analysis of morphology of adrenal pheochromocytoma as regards their potential malignancy].

Kajor M, Ziaja J, Lange D, Król R, Ciupińska-Kajor M, Turska-d'Amico M, Maka B, Cierpka L.

Endokrynol Pol. 2005 Nov-Dec;56(6):911-6. Polish.

PMID:
16821210
17.

Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.

Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E.

Surgery. 2004 Dec;136(6):1129-37.

PMID:
15657566
18.

Pheochromocytomas, PASS, and immunohistochemistry.

Carlsen E, Abdullah Z, Kazmi SM, Kousparos G.

Horm Metab Res. 2009 Sep;41(9):715-9. doi: 10.1055/s-0029-1238274. Epub 2009 Aug 28. Review.

PMID:
19718615
19.
20.

CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas.

August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, Kersting C, Buerger H.

Mod Pathol. 2004 Sep;17(9):1119-28.

Supplemental Content

Support Center